Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,541.89
(
-0.98%
)
US TECH 100
23,352.40
(
-1.55%
)
Dow Jones
45,796.94
(
-0.49%
)
Brent Oil
106.97
(
2.43%
)
Bitcoin
69,954.01
(
0.08%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: oc631 post# 103598

Tuesday, 09/07/2010 11:45:15 AM

Tuesday, September 07, 2010 11:45:15 AM

Post# of 257262

If this was true why did the FDA halt individual testing on IDX184 and IDX320?

IDIX didn’t—the FDA did.

As you stated the DDI study came up clean…

No—the DDI study (in healthy volunteers) is the one that encountered the problem.

IDX184 had previously shown unexplained tox signals at higher doses…

There were no safety signals of undue consequence when IDX184 was given as monotherapy or in combination with SoC.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today